Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: A phase II study

Journal of Clinical Oncology

Volumn 16, Issue 4, 1998, Pages 1438-1443

  Reichardt, Refer ^a   Tilgner, Julia ^a   Hohenberger, Peter ^a   Dörken, Bernd ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPIRUBICIN; IFOSFAMIDE; MESNA; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CENTRAL VENOUS CATHETERIZATION; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; HEART ARRHYTHMIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; METASTASIS; NEPHROTOXICITY; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; SOFT TISSUE SARCOMA; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0344110204     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.4.1438     Document Type: Article

References (42)

1. Brennan MF, Casper ES, Harrison LB: Soft tissue sarcoma, in De Vita VT, Hellman S, Rosenberg SA (eds): Cancer, Principles and Practice of Oncology (ed 5). Philadelphia, PA, Lippincott-Raven, 1997, pp 1738-1788
2. Blackstein ME, Eisenhauer EA, Bramwell V, et al: Docetaxel (Taxotere) as first line therapy for metastatic or recurrent soft tissue sarcoma (STS): A phase II trial. Eur J Cancer 31A: 177, 1995 (suppl 5; abstr)
3. Waltzman R, Schwartz GK, Shorter S, et al: Lack of efficacy of paclitaxel (Taxol) in patients with advanced soft tissue sarcoma (STS). Proc Am Soc Clin Oncol 15:526, 1996 (abstr)
4. Verweij J, Judson I, Crowther D, et al: Randomized study comparing docetaxel (Taxotere) to doxorubicin in previously untreated soft tissue sarcomas. Proc Am Soc Clin Oncol 16:496a, 1997 (abstr)
5. Gottlieb JA, Baker LH, O'Bryan RM, et al: Adriamycin (NSC-123127) used alone and in combination for soft tissue and bony sarcomas. Cancer Chemother Rep 6:271-282, 1975
6. Yap BS, Baker LH, Sinkovics JG, et al: Cyclophosphamide, vincristine, Adriamycin, and DTIC (CYVADIC) combination chemotherapy for the treatment of advanced sarcomas. Cancer Treat Rep 64:93-98, 1980
7. Bodey GP, Rodriguez V, Murphy WK, et al: Protected environment - Prophylactic antibiotic program for malignant sarcomas: Randomized trial during remission induction chemotherapy. Cancer 47:2422-2429, 1981
8. Pinedo HM, Bramwell VH, Mouridsen HT, et al: Cyvadic in advanced soft tissue sarcoma: a randomized study comparing two schedules. A study of the EORTC Soft Tissue and Bone Sarcoma Group. Cancer 53:1825-1832, 1984
9. Bramwell VHC: Chemotherapy for metastatic soft tissue sarcomas - Another full circle? Br J Cancer 64:7-9, 1991
10. Santoro A, Tursz T, Mouridsen H, et al: Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: A randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 13:1537-1545, 1995
11. Bramwell VHC, Mouridsen HT, Santoro A, et al: Cyclophosphamide versus ifosfamide: Final report of a randomized phase II trial in adult soft tissue sarcomas. Eur J Cancer Clin Oncol 23:311-321, 1987
12. Elias AD, Eder JP, Shea T, et al: High-dose ifosfamide with mesna uroprotection: A phase I study. J Clin Oncol 8:170-178, 1990
13. Mansi JL, Fisher C, Wiltshaw E, et al: A phase I-II study of ifosfamide in combination with Adriamycin in the treatment of adult soft tissue sarcoma. Eur J Cancer Clin Oncol 24:1439-1443, 1988
14. Loehrer PJ, Sledge GW, Nicaise C, et al: Ifosfamide plus doxorubicin in metastatic adult sarcomas: A multi-institutional phase III trial. J Clin Oncol 7:1655-1659, 1989
15. Schütte J, Mouridsen HT, Steward W, et al: Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. Eur J Cancer 26:558-561, 1990
16. Weh HJ, Zügel M, Wingberg D, et al: Chemotherapy of metastatic soft tissue sarcoma with a combination of Adriamycin and DTIC or Adriamycin and ifosfamide. Onkologie 13:448-452, 1990
17. Elias A, Ryan L, Sulkes A, et al: Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol 7:1208-1216, 1989
18. Edmonson JH, Ryan LM, Blum RH, et al: Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 11:1269-1275, 1993
19. O'Bryan RM, Baker LH, Gottlieb JB, et al: Dose response evaluation of Adriamycin in human neoplasia. Cancer 39:1940-1948, 1977
20. Borden EC, Amato DA, Rosenbaum C, et al: Randomized comparison of three Adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol 5:840-850, 1987
21. Patel SR, Vadhan-Raj S, Trevino C, et al: Phase II study of high dose ifosfamide + G-CSF in patients with malignant bone tumors and metastatic soft-tissue sarcomas. Proc Am Soc Clin Oncol 11:413, 1992 (abstr)
22. Cerny T, Leyvraz S, Dazzi H, et al: Phase II trials of ifosfamide and mesna in advanced soft tissue sarcoma patients: A definite dose-response relationship. Proc Am Soc Clin Oncol 11:416, 1992 (abstr)
23. Steward WP, Verweij J, Somers R et al: Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: A study of the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 11:15-21, 1993
24. Mouridsen HT, Bastholt L, Somers R, et al: Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer Clin Oncol 23:1477-1483, 1987
25. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
26. Toma S, Palumbo R, Canavese G, et al: Ifosfamide plus epirubicin at escalating doses in the treatment of locally advanced and/or metastatic sarcomas. Cancer Chemother Pharmacol 31:222-221, 1993 (suppl 2)
27. Carpano S, Vici P, Di Lauro L, et al: Treatment of advanced soft tissue sarcomas (STS) with high dose epirubicin (HD-EPI). Proc Am Soc Clin Oncol13:481, 1994 (abstr)
28. Frustaci S, Buonadonna A, Favaro D, et al: Effectiveness of intensive chemotherapy in metastatic soft tissue sarcomas and ability to mobilize PBPC. Proc Am Soc Clin Oncol 13:474, 1994 (abstr)
29. Benjamin RS, Legha SS, Patel SR, et al: Single-agent ifosfamide studies in sarcomas of soft tissue and bone: The M.D. Anderson experience. Cancer Chemother Pharmacol 31:174-179, 1993 (suppl 2)
30. Le Cesne A, Antoine E, Spielmann M, et al: High-dose ifosfamide: Cicumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol 13:1600-1608, 1995
31. Reichardt P, Tilgner J, Sachs U, et al: High-dose ifosfamide in heavily pretreated patients with bone and soft tissue sarcoma. Ann Hematol 73:A100, 1996 (suppl 2; abstr)
32. Chevallier B, Leyraz S, Olivier JP, et al: Epirubicin and iosfamide in advanced soft tissue sarcoma: A phase II study. Cancer Invest 11:135-139, 1993
33. Frustaci S, Buonadonna A, Galligioni E, et al: Increasing 4′-epidoxorubicin and fixed ifosfamide doses plus granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A pilot study. J Clin Oncol 15:1418-1426, 1997
34. Patel SR, Vadhan-Raj S, Burgess MA, et al: Dose intensive therapy does improve response rates - Updated results of Adriamycin in ifosfamide with growth factors in patients with untreated soft tissue sarcomas. Proc Am Soc Clin Oncol 16:499a, 1997 (abstr)
35. Antman K, Crowley J, Balcerzak SP, et al: An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 11:1276-1285, 1993
36. Tursz T, Verweij J, Judson I, et al: Is high-dose chemotherapy of interest in advanced soft tissue sarcomas? An EORTC randomized phase III trial. Proc Am Soc Clin Oncol 15:337, 1996 (abstr)
37. van Oosterom AT, Krzemienlecki K, Nielsen OS, et al: Randomized phase II study of the EORTC Soft Tissue and Bone Sarcoma Group comparing two different ifosfamide regimens in chemotherapy untreated advanced soft tissue sarcoma patients. Proc Am Soc Clin Oncol 16:496a, 1997 (abstr)
38. Zalupski M, Metch B, Balcerzak S, et al: Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: A Southwest Oncology Group study. J Natl Cancer Inst 83:926-932, 1991 (abstr)
39. Van Glabbeke M, van Oosterom AT, Oosterhuis JW, et al: Prognostic factors in advanced soft tissue sarcoma: An overview of 1742 patients treated with doxorubicin containing first line regimens by the EORTC Soft Tissue and Bone Sarcoma Group. Proc Am Soc Clin Oncol 13:474, 1994 (abstr)
40. Rosen G, Forscher C, Lowenbraun S, et al: Synovial sarcoma. Uniform response of metastases to high dose ifosfamide. Cancer 73:2506-2511, 1994
41. Reichardt P, Lentzsch S, Hohenberger P, et al: Dose intensive treatment with ifosfamide, epirubicin and filgrastim for patients with metastatic or locally advanced soft tissue sarcoma. Proc Am Soc Clin Oncol 14:518, 1995 (abstr)
42. Pisters PWT, Patel SR, Varma DGK, et al: Pathologic complete response following preoperative multimodality therapy for stage IIIB extremity soft tissue sarcoma: Implications for the design of multimodality trials. Proc Am Soc Clin Oncol 16:499a, 1997 (abstr)